Lumira Capital invests in $40 mln Series D funding of Celtaxsys
Celtaxsys Inc, a clinical-stage drug development company focused on developing therapies for inflammatory diseases, has raised US$40 million in a Series D financing. The round was led by U.S. venture capital firm Domain Associates and was joined by several other investors, including Canadian firm Lumira Capital. Celtaxsys, which is headquartered in Atlanta, Georgia, said the proceeds of the round will help fund the company's novel anti-inflammatory Phase Two programs in cystic fibrosis and acne. As a result of the financing, Gerry Brunk, a managing director at Lumira, has joined Celtaxsys' board of directors.
8 June 2015•4 mins read
